{"nctId":"NCT01120028","briefTitle":"Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy","startDateStruct":{"date":"2010-09","type":"ACTUAL"},"conditions":["Kidney Transplantation"],"count":852,"armGroups":[{"label":"Alemtuzumab/Sirolimus","type":"EXPERIMENTAL","interventionNames":["Drug: Alemtuzumab","Drug: Sirolimus"]},{"label":"Alemtuzumab/Tacrolimus","type":"EXPERIMENTAL","interventionNames":["Drug: Alemtuzumab","Drug: Tacrolimus"]},{"label":"Basiliximab/Tacrolimus","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Basiliximab","Drug: Tacrolimus"]},{"label":"Basiliximab/Sirolimus","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Basiliximab","Drug: Sirolimus"]}],"interventions":[{"name":"Alemtuzumab","otherNames":["Campath-1H"]},{"name":"Basiliximab","otherNames":["Simulect"]},{"name":"Sirolimus","otherNames":["Rapamune"]},{"name":"Tacrolimus","otherNames":["Prograf"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* men or women aged over 18 years\n* recipient of kidney transplant (planned in next 24 hours)\n\nExclusion Criteria:\n\n* recipients of multi-organ transplant\n* previous treatment with Campath-1H\n* active infection (including HIV, hepatitis B or C)\n* history of anaphylaxis to humanized monoclonal antibody\n* history of malignancy (except adequately treated non-melanoma skin cancer)\n* loss of kidney transplant within 6 months not due to technical reasons\n* medical history that might limit the individual's ability to take trial treatments for the duration of the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Biopsy-proven Acute Rejection at 6-months After Randomization to Induction Therapy","description":"Occurence of biopsy-proven acute rejection events at 6-months after transplantation during Period 1 (randomization to induction therapy (Campath-1H and Tacrolimus, or Basiliximab and Tacrolimus))","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"68","spread":null}]}]}]},{"type":"PRIMARY","title":"Graft Function (at 18-months After Randomization to Maintenance Therapy)","description":"Estimated glomerular filtration rate (estimated using MDRD formula) at 18-months after maintenance therapy randomization to either Sirolimus or Tacrolimus.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.7","spread":"0.9"},{"groupId":"OG001","value":"54.6","spread":"0.9"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Graft Failure (at 6-months After Randomization to Induction Therapy)","description":"Return to dialysis or re-transplantation by 6-months after randomization to induction therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Graft Failure (at 18-Months After Randomization to Maintenance Therapy)","description":"Return to dialysis or re-transplantation by 18-months after randomization to maintenance therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Serious Infection (at 6-months After Randomization to Induction Therapy)","description":"Occurrence of any serious infection (opportunistic or requiring admission to hospital) reported within Period 1 (randomization to induction therapy of either Alemtuzumab (Campath-1H) and Tacrolimus, or Basiliximab and Tacrolimus).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"135","spread":null},{"groupId":"OG001","value":"136","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Serious Infection (at 18-months After Randomization to Maintenance Therapy)","description":"Occurrence of any serious infection (opportunistic or requiring admission to hospital) reported during Period 2 (maintenance therapy randomization to either Sirolimus or Tacrolimus).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"70","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Cancer (at 18-months After Randomization to Maintenance Therapy)","description":"Occurrence of any cancer reported during Period 2 (maintenance therapy randomization to either Sirolimus or Tacrolimus).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Major Vascular Event (at 18-months After Randomization to Maintenance Therapy)","description":"Composite of non-fatal myocardial infarction, non-fatal stroke, cardiovascular death or arterial revascularization","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":341,"n":426},"commonTop":[]}}}